Literature DB >> 1943116

Clinical usefulness of chemosensitivity testing using the MTT assay.

T Furukawa1, T Kubota, A Suto, T Takahara, H Yamaguchi, T Takeuchi, S Kase, S Kodaira, K Ishibiki, M Kitajima.   

Abstract

The results of in vitro chemosensitivity testing using the MTT assay of tumor cells from 140 patients were analyzed with reference to the clinical antitumor effects of the chemotherapy. One hundred and twenty-four (88.6%) of 140 specimens were successfully tested by the method of Mosmann (J Immunol Methods 65:55-63, 1983) with some modifications. When the results of the assay were compared with the clinical effects of chemotherapy in 22 patients with remaining measurable tumor lesions, the overall prediction rate was 86.4% (19/22). Among 31 patients with stage III-V gastric and colorectal carcinomas without remaining measurable tumor lesions, the survival rate of nine patients treated with drugs shown to be effective in the assay was significantly (P less than 0.05) better than that of 22 patients treated with drugs shown to be ineffective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1943116     DOI: 10.1002/jso.2930480310

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

Review 1.  Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question.

Authors:  Tetsuro Kubota; Larry Weisenthal
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

2.  Serial growth of human malignant fibrous histiocytoma xenografts in immunodeficient mice.

Authors:  N Kurihara; T Kubota; Y Otani; M Watanabe; K Kumai; M Kitajima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

3.  Towards hemerythrin-based blood substitutes: comparative performance to hemoglobin on human leukocytes and umbilical vein endothelial cells.

Authors:  Eva Fischer-Fodor; Augustin Mot; Florina Deac; Mariann Arkosi; Radu Silaghi-Dumitrescu
Journal:  J Biosci       Date:  2011-06       Impact factor: 1.826

4.  The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.

Authors:  H Zhao; M-S Chen; Y-H Lo; S E Waltz; J Wang; P-C Ho; J Vasiliauskas; R Plattner; Y-L Wang; S-C Wang
Journal:  Oncogene       Date:  2013-04-01       Impact factor: 9.867

5.  A new polyethyleneglycol-derivatized hemoglobin derivative with decreased oxygen affinity and limited toxicity.

Authors:  Oana Zolog; Augustin Mot; Florina Deac; Alina Roman; Eva Fischer-Fodor; Radu Silaghi-Dumitrescu
Journal:  Protein J       Date:  2011-01       Impact factor: 2.371

6.  Comparative in vitro cytotoxicity of ethyl acrylate and tripropylene glycol diacrylate to normal human skin and lung cells.

Authors:  L A Nylander-French; J E French
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-10       Impact factor: 2.416

7.  Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.

Authors:  David H Lum; Cindy Matsen; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2012-12

8.  The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.

Authors:  S Kase; T Kubota; M Watanabe; T Takahara; T Takeuchi; H Yamaguchi; T Furukawa; T Teramoto; S Kodaira; K Ishibiki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  A simplified in vitro model of oxidant injury using vascular endothelial cells.

Authors:  L Li; B H Lau
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-07       Impact factor: 2.416

10.  A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.

Authors:  Kazumichi Abe; Takeru Wakatsuki; Fumiko Katsushima; Kyoko Monoe; Yukiko Kanno; Atsushi Takahashi; Junko Yokokawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.